Fig. 3From: Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimensOverall survival among patients with AML-MRC preselected to LDAC. a Overall survival for patients with AML-MRC treated with azacitidine or LDAC; b Overall survival by cytogenetic risk; c Overall survival by age groupBack to article page